Faron Pharmaceuticals Oy (LON:FARN) Stock Price Up 0.1% - What's Next?

Key Points

• Faron Pharmaceuticals Oy stock increased by 0.1% during mid-day trading, reaching a last traded price of GBX 175.10 ($2.35) with a significant trading volume of 174,835 shares, up 432% from the average.
• The company has a debt-to-equity ratio of 922.55 and a market capitalization of £196.03 million, indicating high financial leverage.
• Faron is developing innovative treatments for unmet medical needs, including Clevegen, a promising investigational immunotherapy with potential applications in oncology and infectious diseases.

Faron Pharmaceuticals Oy (LON:FARN - ) shot up 0.1% during mid-day trading on Tuesday . The stock traded as high as GBX 182.20 ($2.45) and last traded at GBX 175.10 ($2.35). 174,835 shares traded hands during mid-day trading, an increase of 432% from the average session volume of 32,861 shares. The stock had previously closed at GBX 175 ($2.35).

Faron Pharmaceuticals Oy Trading Up 0.1%

The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The firm has a market capitalization of £196.03 million, a PE ratio of -648.52 and a beta of 0.36. The firm's fifty day moving average is GBX 200.98 and its two-hundred day moving average is GBX 208.86.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.